| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c476f50ba77ab8ef26b22f3154901689
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac5c6221abeb31a64e2cf4aa3fe52a18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42c5d2df2b0f6907d5050acf9970562e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_530d85c1ffef1eb8545a76cd43dfb758
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fc6c2e9e63b6561f2f46b1de31f6379 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0006 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate |
2003-02-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9fa17c4aef91f136a9fc76adb7a56ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdaa6f4349094ddd9d78eb5248e38338
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb9bdad1ddc2d8162516d82cab744d96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fb969d3ec9f653067bd75cf1dc880f8 |
| publicationDate |
2003-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03068153-A2 |
| titleOfInvention |
CARDIAC-SPECIFIC 11β HYDROXYSTEROID DEHYDROGENASE TYPE 2 TRANSGENIC MICE |
| abstract |
Five independent transgenic founder lines were created which have all developed cardiac hypertrophy and heart failure. The line with the most severe phenotype was analyzed in detail. Transgenic cardiac 11β3HSD2 mRNA expression is increased 4,000 fold over non-transgenic mice and the expressed enzyme was found to possess catalytic activity. At five months of age transgenic mice had developed severe myocardial hypertrophy in the absence of an increase in blood pressure. Interstitial fibrosis in the left ventricle of transgenic mice was revealed by picrosirius red staining. The hearts of the mice were severely dilated and cardiomyocyte size was increased. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103173451-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103173451-A |
| priorityDate |
2002-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |